Day: August 12, 2022

MONROE TOWNSHIP, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced that it will report its fiscal 2023 first quarter after the market closes on Monday, September 12, 2022. CONFERENCE CALL AND WEBCAST INFORMATION A conference call to discuss the financial results will be held the following morning Tuesday, September 13, 2022, at 9:00 a.m. Eastern time. Philipp Stratmann, CEO, Bob Powers, CFO, and Joseph Dipietro, Treasurer and Controller, will host the call.The dial-in numbers for the conference call are 877-407-8291 or 201-689-8345. Live webcast: Link to 1Q23 Webcast for OPTTA replay will be available by telephone approximately...

— Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – — Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D. – — Strengthened Board of Directors with appointment of Diane Seimetz, Ph.D. and leadership team with appointment of Shamik Parikh, M.D. as Chief Medical Officer –  — Multiple scientific meeting presentations and publications highlighting clinical HAV data in vascular trauma and arteriovenous access and preclinical small-diameter HAV data in coronary artery bypass grafting (CABG)– — Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage...

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. “We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a solid tumor cancer trial. Our pancreatic study is not far behind, and we expect to initiate this clinical trial in the third quarter. Next, we...

Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H 2023 with top-line clinical data expected in early 2024 Phase 1 study initiated for ITIL-306, Instil’s first CoStAR-TIL product candidate Phase 1 study initiated for ITIL-168 in combination with pembrolizumab (DELTA-2) for NSCLC, cervical cancer, and squamous cell carcinoma of the head and neck DALLAS, Aug. 12, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2022 financial results...

VAZALORE 81 mg Low-Dose Liquid-Filled Aspirin Capsules The First and Only Liquid-Filled Aspirin CapsulesResults of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred together as “VAZALORE®”), today announced...

CHERRY HILL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), an innovative, high-growth, branded, health- and wellness-focused frozen food company, today reported financial results for its second quarter ended June 30, 2022. “I am pleased with our solid second quarter revenue growth driven by both new and existing customers,” said Bryan Freeman, Executive Chairman. “We have seen strong growth in retail grocery, exhibited by our sustained velocity momentum, as well as growth in the unmeasured channel. This gives us confidence in our updated outlook for 2022. We believe we are still in the early innings of growth and continue to pursue our mission to make nutritious comfort foods that are low in carbohydrates, high in protein, and made from gluten and grain...

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Spruce Ridge Resources Ltd. (“Spruce” or the “Company”) (TSX-V: SHL) announces that Robert Suttie has been appointed as Chief Financial Officer of the Company effective today, replacing the Company’s CFO, Mr. Zoran Popovic. Mr. Suttie currently works with Marrelli Support Services as its President, possessing more than 20 years of experience, ten of which were in public accounting prior to his tenure with the Marrelli organization. Mr. Suttie specializes in management advisory services, accounting and the financial disclosure needs of the Marrelli group’s public client base. Mr. Suttie also serves as Chief Financial Officer for several other junior mining and technology companies listed on the TSX-V and CSE, leveraging his skills and experience to become integral to the reporting issuers. The...

A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as measured by central subfield thickness (CST) at 12- and 18-weeks, as compared to worsening in sham-treated patients The treatment effect was seen in a patient population with visual acuity deficits and residual retinal fluid despite frequent and recent anti-VEGF therapy UNITY to host investor call with retinal expert Robert Bhisitkul, M.D., Ph.D., today, August 12, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...

~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Commercialization of PEDMARKTM ~ RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the fiscal quarter ended June 30, 2022 and provided a business update. “We have made significant progress toward the potential launch of PEDMARKTM in the U.S. for cisplatin induced...

Revenue Exceeds Expectations, Growth Initiatives Remain on TrackUpdates Full Year 2022 Outlook for Cost Pressures LOS ANGELES, Aug. 12, 2022 (GLOBE NEWSWIRE) — The Honest Company (NASDAQ: HNST), a digitally native, mission-driven brand focused on leading the clean lifestyle movement, today reported financial results for the three and six months ended June 30, 2022. HighlightsSecond quarter revenue growth of 5%, led by a 9% increase in diapers and wipes Strategic initiatives remain on track for execution of innovation, new retail distribution and pricing Maintains full year 2022 revenue outlook, reflecting mid-single digit growth for the remainder of the year Updates full year gross margin outlook, which reflects sequential improvement in the second half of 2022 Updates full year Adjusted EBITDA(1) outlook, including positive...